Supplemental Table 1 from Synthesizing a Smarter CAR T Cell: Advanced Engineering of T-cell Immunotherapies

Zhu, Iowis; Piraner, Dan I.; Roybal, Kole T.

doi:10.1158/2326-6066.30720882

Supplemental Table 1 from Synthesizing a Smarter CAR T Cell: Advanced Engineering of T-cell Immunotherapies

https://doi.org/10.1158/2326-6066.30720882

journal contribution

posted on 2025-11-26, 12:43 authored by Iowis Zhu, Dan I. Piraner, Kole T. Roybal

<p>Summary of chimeric immune receptors designed to incorporate multiple intracellular signaling domains distributed among discrete polypeptide chains.</p>

Funding

Parker Institute for Cancer Immunotherapy (Parker Institute)

History

Related Materials

1.
DOI - Is supplement to Synthesizing a Smarter CAR T Cell: Advanced Engineering of T-cell Immunotherapies

ARTICLE ABSTRACT

The immune system includes an array of specialized cells that keep us healthy by responding to pathogenic cues. Investigations into the mechanisms behind immune cell behavior have led to the development of powerful immunotherapies, including chimeric-antigen receptor (CAR) T cells. Although CAR T cells have demonstrated efficacy in treating blood cancers, issues regarding their safety and potency have hindered the use of immunotherapies in a wider spectrum of diseases. Efforts to integrate developments in synthetic biology into immunotherapy have led to several advancements with the potential to expand the range of treatable diseases, fine-tune the desired immune response, and improve therapeutic cell potency. Here, we examine current synthetic biology advances that aim to improve on existing technologies and discuss the promise of the next generation of engineered immune cell therapies.

Supplemental Table 1 from Synthesizing a Smarter CAR T Cell: Advanced Engineering of T-cell Immunotherapies

Funding

Parker Institute for Cancer Immunotherapy (Parker Institute)

History

Related Materials

ARTICLE ABSTRACT

Usage metrics

Categories

Keywords

Licence

Exports